 |
|
|
|
Weight loss improves health in patients with type 2 diabetes. It has been shown to “ameliorate
insulin resistance, to improve carbohydrate tolerance and to reduce hyperglycemia and
hyperinsulinemia.” 5
Published studies have shown that serum glucose levels began to improve within days after
starting a weight-loss program – even on a moderately hypocaloric (1200 to 1500 calories/day)
diet.48 Weight reduction in patients with type 2 diabetes also lead to increases in HDL
cholesterol levels.5
XENICAL is indicated for obesity management in patients with an initial body mass index (BMI)
of 30 or more and in patients with a BMI of 27 or more in the presence of other risk factors
(eg, hypertension, diabetes, dyslipidemia). After 6 months, 72% of patients lost 5% or more
of their initial body weight, with a mean loss of 23 lbs. Weight loss has been shown to reduce
or eliminate the need for diabetic drug therapy.47 It has also been demonstrated in a modest
number of studies to improve abnormally low insulin sensitivity and coronary risk – promoting
plasma lipoprotein levels found in obese subjects with the prediabetic condition known as
syndrome X.21,22
Specific Health Benefits:
Delay in onset of type 2 diabetes and treatment with XENICAL.
- In the four-year XENDOS study, the effects of orlistat on weight loss and in delaying the onset of type 2 diabetes was compared to placebo in 3304 obese patients who had either normal or impaired glucose tolerance at baseline. At the end of the 1st year of treatment, 73% of the XENICAL treated patients and 45% of the placebo treated patients had a >5% weight loss. After four years, the relative risk reduction for developing type 2 diabetes in patients with impaired glucose tolerance was 42% less in the diet plus XENICAL group compared to the diet plus placebo group(p<0.01). In addition, greater reductions in total cholesterol, LDL-cholesterol, LDL/HDL ratio, fasting insulin systolic and diastolic blood pressure and waist circumference were observed in diet plus XENICAL treated patients compared to diet plus placebo treated patients.
Type 2 diabetes and treatment with XENICAL
- In a study of patients with type 2 diabetes stabilized on sulfonylureas, 30% of the patients treated with XENICAL achieved at least a 5% or greater reduction in body weight after one year of treatment compared to 13% of the placebo treated patients. The XENICAL plus sulfonylurea treated patients also achieved significant reductions in sulfonylurea usage and dose reduction as well as significant reductions in HbA1c and fasting glucose compared to the placebo plus sulfonylurea treatment group. In addition treatment with XENICAL plus sulfonylurea was associated with significant reductions in total cholesterol, LDL-cholesterol, LDL/HDL ratio and triglycerides compared to placebo plus sulfonylurea treatment group.
The long-term effects of XENICAL (orlistat) on morbidity and mortality associated with obesity have not
been established.
Managing Patients with Obesity-Related Comorbidities
More about Obesity as a Clinical Condition
|
|
|
